Shattuck Labs will host an investor call on June 8, 2026, to present Phase 1 data for SL-325.
Quiver AI Summary
Shattuck Labs, Inc., a clinical-stage biotechnology company focused on developing innovative DR3-blocking antibodies for inflammatory and immune-mediated diseases, announced an upcoming investor call and webcast on June 8, 2026, at 8:00 a.m. ET. The event will present detailed Phase 1 clinical data for SL-325, a potentially first-in-class DR3 blocking antibody, covering various aspects such as safety, tolerability, and pharmacodynamics, along with an update on the company's pipeline. Key members of Shattuck's management team will present during the call, followed by a question-and-answer session. SL-325 is noted for its high affinity binding and promising safety profile, and the webcast will be accessible on the company’s website with a replay available for 30 days afterward.
Potential Positives
- Announcement of an investor call to present comprehensive Phase 1 clinical data for SL-325, showcasing transparency and engagement with investors.
- Data from preclinical studies demonstrate that SL-325 shows high affinity binding and superior activity over existing TL1A antibodies, indicating strong potential for efficacy.
- SL-325 is a potentially first-in-class therapy targeting the DR3/TL1A pathway, positioning Shattuck Labs at the forefront of innovation in the treatment of inflammatory and immune-mediated diseases.
Potential Negatives
- Details about the safety, tolerability, and overall effectiveness of SL-325 are not disclosed in the press release, which may raise concerns among investors regarding the product's viability.
- The reliance on a Phase 1 clinical trial, which is an early stage of testing, could indicate that the product is far from market readiness, potentially causing skepticism about the company's progress.
- There is no mention of partnerships or collaborations that could strengthen the development or commercialization of SL-325, possibly suggesting limited external validation or support for the product.
FAQ
What is the purpose of the June 8, 2026 investor call?
The call will present Phase 1 clinical data for SL-325 and provide a pipeline update.
Who will be presenting during the investor call?
Presenters include Shattuck's CEO, CMO, CSO, VP of Clinical Development, and CFO.
How can I access the investor call webcast?
You can access the live webcast on Shattuck’s website under the Events & Presentations section.
What is SL-325?
SL-325 is a potentially first-in-class DR3-blocking antibody aimed at treating inflammatory and immune-mediated diseases.
Where does Shattuck Labs operate?
Shattuck Labs has offices in Austin, Texas, and Durham, North Carolina.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STTK Insider Trading Activity
$STTK insiders have traded $STTK stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $STTK stock by insiders over the last 6 months:
- ARUNDATHY N. PANDITE (Chief Medical Officer) sold 30,000 shares for an estimated $198,300
- ABHINAV A. SHUKLA (Chief Technical Officer) sold 2,032 shares for an estimated $14,244
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$STTK Hedge Fund Activity
We have seen 54 institutional investors add shares of $STTK stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROSIGHT MANAGEMENT, LP added 2,622,937 shares (+110.1%) to their portfolio in Q1 2026, for an estimated $16,865,484
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,661,170 shares (-26.3%) from their portfolio in Q1 2026, for an estimated $10,681,323
- BANK OF AMERICA CORP /DE/ removed 1,026,693 shares (-92.8%) from their portfolio in Q1 2026, for an estimated $6,601,635
- AMERIPRISE FINANCIAL INC added 894,207 shares (+7775.7%) to their portfolio in Q1 2026, for an estimated $5,749,751
- ABERDEEN GROUP PLC added 628,144 shares (+118.3%) to their portfolio in Q1 2026, for an estimated $4,038,965
- 683 CAPITAL MANAGEMENT, LLC removed 590,000 shares (-42.4%) from their portfolio in Q1 2026, for an estimated $3,793,700
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 567,538 shares (+382.4%) to their portfolio in Q1 2026, for an estimated $3,649,269
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$STTK Analyst Ratings
Wall Street analysts have issued reports on $STTK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 04/27/2026
- Piper Sandler issued a "Overweight" rating on 01/28/2026
To track analyst ratings and price targets for $STTK, check out Quiver Quantitative's $STTK forecast page.
$STTK Price Targets
Multiple analysts have issued price targets for $STTK recently. We have seen 4 analysts offer price targets for $STTK in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $7.0 on 06/05/2026
- David Nierengarten from Wedbush set a target price of $11.0 on 05/08/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $18.0 on 04/20/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $15.0 on 01/28/2026
Full Release
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it will host an investor call and webcast on Monday, June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update.
The event will feature presentations by members of Shattuck’s management team, including Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Lini Pandite, M.D., M.B.A., Chief Medical Officer, Suresh De Silva, Ph.D., Chief Scientific Officer, Michael Choi, M.D., Vice President of Clinical Development, and Andrew Neill, M.B.A., Chief Financial Officer, followed by a question-and-answer session.
Conference Details
Title
: Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update
Date & Time:
Monday, June 8, 2026 at 8:00 a.m. ET
Webcast Details:
Click here
Interested parties can access the live webcast via the Events & Presentations section of the Company’s website at www.shattucklabs.com . A replay of the webcast will be available for approximately 30 days following the event.
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced, fully human immunoglobulin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
[email protected]
